The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
about
Memantine inhibits α3β2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteriesMemantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapsesNeural Protein Synthesis during Aging: Effects on Plasticity and MemoryChronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptorsKynurenine 3-Monooxygenase: An Influential Mediator of NeuropathologyTowards medication-enhancement of cognitive interventions in schizophreniaThe Role of Hippocampal NMDA Receptors in Long-Term Emotional Responses following Muscarinic Receptor ActivationAlzheimer's disease: Targeting the Cholinergic SystemPharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular diseaseAre we studying and treating schizophrenia correctly?PHARMACOLOGICAL TREATMENTS FOR TINNITUS: NEW AND OLDEmerging pharmacotherapy of tinnitus.Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein.Pharmacodynamics of memantine: an update.Potential role of the combination of galantamine and memantine to improve cognition in schizophreniaAutophagy of mitochondria: a promising therapeutic target for neurodegenerative disease.Fragile X syndrome: an update on developing treatment modalities.Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivativesProtection from glutamate-induced excitotoxicity by memantineCrossover trial of gabapentin and memantine as treatment for acquired nystagmus.Clinical features and multidisciplinary approaches to dementia care.Recent insights into the mode of action of memantine and ketamineIn vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agentsPotential natural products for Alzheimer's disease: targeted search using the internal ribosome entry site of tau and amyloid-β precursor protein.The dichotomy of memantine treatment for ischemic stroke: dose-dependent protective and detrimental effects.Contribution of N-methyl-D-aspartate receptors to attention and episodic spatial memory during senescence.Development of the calcium plateau following status epilepticus: role of calcium in epileptogenesis.Effects of memantine on event-related potential, oscillations, and complexity in individuals with and without family histories of alcoholism.Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease.Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in ratsMemantine: efficacy and safety in mild-to-severe Alzheimer's disease.Memantine and dizocilpine interactions with antinociceptive or discriminative stimulus effects of morphine in rats after acute or chronic treatment with morphine.Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain.L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner.Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.Senescent synapses and hippocampal circuit dynamics.
P2860
Q21134148-10CB0E94-A122-4D72-969F-00644F2DE075Q24619395-A81FE52C-A08B-47FB-85E4-8D53EC8E52EEQ24625332-9A32532B-C1C3-45E4-A2F3-FDB190098468Q24796326-8FA5AD24-37F7-4B9B-889E-612F54E26CCEQ26782867-9F6F080C-284E-4ABC-8580-EA190491FD24Q26860777-C7CDFD94-DCA7-4B24-A36B-EC5E227A90AEQ27329061-D4BD9766-09B2-46C4-934E-A5E88B5B203EQ28070135-6063BBBE-FB85-4F09-B90D-4F345EE026BBQ29243373-6D7849ED-8D6E-4D16-B124-8C7DBAD041D0Q30465313-BD4BF3D2-5BAE-4E1F-BDC9-57D233347F03Q30474822-5BDB879F-008B-408B-BCB0-B37DE39E984CQ30478378-649FF826-B5F8-4717-A0E5-E51A4E119C07Q30481489-3932B108-8882-402B-8E6E-255B900DA3E7Q30490604-0E1227E1-8140-4C4F-BFB6-F9F6056C7D59Q33905343-454E5E8F-EF0C-41DD-A1BD-C72DD8F8F10AQ34287719-2E465024-392E-4394-8D90-4FBACEAB13F5Q34292108-9B2CA71D-82BE-449C-BDF7-081F56D2862BQ34301111-FD724C96-7ED2-4546-9198-56E141484BABQ34329204-5AEF9995-F5E5-46AD-85AF-4876EA9C0C90Q34442727-89A1160A-4E09-425A-9BF6-0EF8CD56DC68Q34722007-18BBCD4D-E990-40D4-B14B-981B42C5F4E8Q35015449-8937A270-60EB-48CD-A562-482FB21EFB6CQ35054539-456207A4-F7EE-44C2-8CDB-9BDF3ED4E40CQ35103820-F5129800-4BAC-4F1E-8990-7F8EF54E3BD5Q35546008-2E3A6B65-6AD8-48DE-94D3-4A7D043BCDA1Q35585744-7E385EF1-7DAB-4FC8-8151-29D4FAA1FCCBQ35591224-DA8B3E8D-E34D-4A0F-B0F7-B912016DB0B8Q36289349-8A763531-A83B-4512-BDD4-59628DF01199Q36333307-9A244409-948A-4168-AF14-5383762B89A0Q36597555-4743AAED-ACAC-40E8-A50D-B33F7A454DF6Q36919155-6FB246CA-319B-4FBC-BD17-A3E7C4D1D8E3Q37035894-AFCF2DA6-D43D-46AF-9AE6-67749DDA3467Q37045455-449FF4BD-F71C-453E-85E8-012D5CA8652FQ37125743-982BB294-D5FC-47BD-8404-1C62DA251B8DQ37183549-FF15E371-51C3-4120-9B14-DEB5852CC744Q37184807-779D8362-8FE7-4EAE-B17E-51B0F6484824Q37345125-B711C93D-2D5B-4DCC-8AEF-D337C8982A0CQ37395774-788E8C15-E0B9-44DF-8175-1984C29BC4D7Q37411683-D8669795-321C-4B6A-9EDC-F1CA5C418B0DQ37673419-F6D90023-F925-492C-988F-6CD4309E231C
P2860
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The neuropharmacological basis ...... atment of Alzheimer's disease.
@ast
The neuropharmacological basis ...... atment of Alzheimer's disease.
@en
The neuropharmacological basis ...... atment of Alzheimer's disease.
@nl
type
label
The neuropharmacological basis ...... atment of Alzheimer's disease.
@ast
The neuropharmacological basis ...... atment of Alzheimer's disease.
@en
The neuropharmacological basis ...... atment of Alzheimer's disease.
@nl
prefLabel
The neuropharmacological basis ...... atment of Alzheimer's disease.
@ast
The neuropharmacological basis ...... atment of Alzheimer's disease.
@en
The neuropharmacological basis ...... atment of Alzheimer's disease.
@nl
P1476
The neuropharmacological basis ...... atment of Alzheimer's disease.
@en
P2093
Gary L Wenk
Michael A Rogawski
P304
P577
2003-01-01T00:00:00Z